Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
0.9292
+0.1592 (20.68%)
At close: Jul 3, 2025, 1:00 PM
0.8681
-0.0611 (-6.58%)
After-hours: Jul 3, 2025, 4:59 PM EDT
Windtree Therapeutics Employees
Windtree Therapeutics had 14 employees as of December 31, 2024. The number of employees decreased by 6 or -30.00% compared to the previous year.
Employees
14
Change
-6
Growth
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,482,071
Market Cap
3.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
WINT News
- 3 days ago - Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - GlobeNewsWire
- 9 days ago - Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel - GlobeNewsWire
- 6 weeks ago - Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - GlobeNewsWire
- 7 weeks ago - Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 - GlobeNewsWire
- 2 months ago - Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US - GlobeNewsWire
- 3 months ago - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - PRNewsWire
- 3 months ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire
- 3 months ago - Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - GlobeNewsWire